Accéder au contenu
MilliporeSigma
Toutes les photos(1)

Documents

Y0000821

Molsidomine

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

N-(Ethoxycarbonyl)-3-(4-morpholino)sydnone imine, SIN-10

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Formule empirique (notation de Hill):
C9H14N4O4
Numéro CAS:
Poids moléculaire :
242.23
Numéro MDL:
Code UNSPSC :
41116107
ID de substance PubChem :
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

molsidomine

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

CCOC(=O)N=C1O[N-][N+](=C1)N2CCOCC2

InChI

1S/C9H14N4O4/c1-2-16-9(14)10-8-7-13(11-17-8)12-3-5-15-6-4-12/h7H,2-6H2,1H3/b10-8-

Clé InChI

XLFWDASMENKTKL-NTMALXAHSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Molsidomine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Pictogrammes

Exclamation mark

Mention d'avertissement

Warning

Mentions de danger

Conseils de prudence

Classification des risques

Acute Tox. 4 Oral

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable


Choose from one of the most recent versions:

Certificats d'analyse (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

[Treatment of myocardial ischemia with molsidomine].
J Dirschinger et al.
Medizinische Klinik (Munich, Germany : 1983), 85(3), 141-144 (1990-03-15)
Effects of molsidomine and other NO-containing vasodilators on cyclic GMP formation.
E Böhme et al.
European heart journal, 4 Suppl C, 19-24 (1983-05-01)
J L Wautier
Presse medicale (Paris, France : 1983), 17(20), 1037-1040 (1988-05-25)
Platelet suppressive agents have been shown to improve the prognosis of coronary diseases such as myocardial infarction and unstable angina. Several markers of platelet activation during myocardial ischemia have been found to be increased. Platelet granule constituents (beta thromboglobulin or
[Nitric oxide in therapy of angina pectoris: nitrates or molsidomine?].
V Schächinger et al.
Der Internist, 38(5), 438-447 (1997-05-01)
R E Nitz et al.
Pharmacotherapy, 7(1), 28-37 (1987-01-01)
The long-acting antianginal drug molsidomine has been shown experimentally to reduce myocardial infarct size when administered prior to or after cardiac insult. This is due to several drug actions. Dilation of postcapillary capacitance vessels diminishes venous return, preload, heart dimensions

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique